Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant–abemaciclib. Primary end points were investigator-assessed progression-free ...

Hope S. Rugo, MD, FASCO, discusses the role of abemaciclib plus elacestrant for ER+/HER2– MBC from data presented at SABCS ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

This page includes links to articles highlighting the top breast cancer research published on Cancer Therapy Advisor in 2024.

Herein we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. Abemaciclib+fulvestrant ...

Arvinas and Pfizer have shared preliminary outcomes from the Phase Ib segment of the TACTIVE-U sub-trial of vepdegestrant plus abemaciclib for treating individuals with locally advanced or ...

The combination of imlunestrant and abemaciclib further enhanced PFS to 9.4 months, regardless of ESR1 mutation status. Consistent benefits were observed across subgroups, including those with ...

Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safety profile for the combination of abemaciclib 150 mg twice daily (BID) with the recommended Phase 3 ...

Alpelisib, we ran into a lot of toxicities, but they were all alpelisib toxicities. So a lower dose will be tested in the next cohort with elacestrant. And then capivasertib [Truqap] is in the early ...

Jhaveri and colleagues also evaluated imlunestrant in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) versus imlunestrant alone among all patients, and found that the combination ...

pro kabaddi 2024 when start New oral TYK2 inhibitor! InnoCare Pharma's Class 1 new drug clinical trial application accepted Hengrui CDK 4/6 inhibitors approved for clinical trials for two indications ...